Breast Cancer: Update Bulletin [March 2016]
In this update KOLs reflect on the promising Phase Ib data for Roche’s monoclonal antibody (mAb), atezolizumab, in combination with nab-paclitaxel for patients with metastatic triple- negative breast cancer (mTNBC); the US Food and Drug Administration (FDA) awarding Breakthrough Therapy Designation to Immunomedics’ lead antibody drug conjugate (ADC), sacituzumab govitecan (IMMU-132), along with reaction to the Phase II trials of IMMU-132 in late stage TNBC; and KOL reaction to an expanded indication to Pfizer’s Ibrance (palbociclib) based on findings from the Phase III PALOMA-3 trial.
Key Questions Answered in this Update Bulletin:
Key Questions Answered in this Update Bulletin:
- How do KOLs feel about the potential of immunotherapy in the area of TNBC, including comparisons with PARP inhibitors?
- What are KOLs first impressions to the Phase Ib data of Roche’s atezolizumab in combination with nab-paclitaxel in patients with mTNBC, what are their concerns?
- How does the approach of immunotherapy compare to that of PARP inhibitors?
- Where in the treatment paradigm could an agent such as atezolizumab be used?
- What are KOLs first impressions to the Phase II data for Immunomedics’ lead antibody drug conjugate sacituzumab govitecan in patients with late stage TNBC?
- Where in the treatment paradigm could an agent such as sacituzumab govitecan be used?
- How do KOLs react to the supplemental filing and subsequent granting of an expanded indication to Pfizer’s Ibrance (palbociclib) based on findings from the Phase III PALOMA-3 trial?
- What impact will the granting of this expanded indication have on prescriptions of Ibrance and on those of Afinitor?
